NCT06246123

A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean Participants

Post Marketing Surveillance of Jyseleca Tab. (Filgotinib Maleate) in Korean Subjects

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 2,040 (estimated)
• Sponsor: Eisai Korea Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to collect and evaluate the following information in relation to the safety and the efficacy of Jyseleca tablet (Filgotinib Maleate) 100 milligram (mg) and 200 mg in this post marketing setting: (1) Serious adverse events and adverse drug reactions (2) Unexpected adverse events and adverse drug reactions not reflected in precautions for use (3) Known adverse drug reactions (4) Non-serious adverse events and adverse drug reactions (5) Other safety and effectiveness related information will be evaluated in accordance with the permitted articles under the actual conditions of use in Korea.

Conditions

• Arthritis, Rheumatoid
• Colitis, Ulcerative

Interventions

Type	Name	Description
OTHER	Non-interventional	No intervention will be administered.

Timeline

• Start date: 2024-02-27
• Primary completion: 2027-07-30
• Completion: 2027-07-30
• First posted: 2024-02-07
• Last updated: 2026-04-07

Locations

64 sites across 1 country: South Korea